



AcceSS and Equity in Transplantation

Project 1: Geographic variation in kidney failure in Aotearoa New Zealand


Johanna Birrell, Angela Webster, Nicholas Cross, Heather Dunckley, Ben Beaglehole, Ian Dittmer, John Irvine, Curtis Walker, Merryn Jones, Melanie Wyld, Kate Wyburn, Nicole De La Mata

Background:

- Transplantation is considered the ideal treatment for most people with kidney failure^{1,2}
 - Survival
 - Quality of life
 - Cost-effectiveness, compared to dialysis
- Key Performance Indicator (Australia & New Zealand Society of Nephrology):
 - Proportion of patients aged 2-64 years who are transplanted or “active” on the waiting list **within 6 months** of starting kidney replacement therapy.³

Background:

- Te Whatu Ora – Health New Zealand
 - Need for data to guide national resource allocation
- ASSET Linked Data Platform
 - Deterministic data linkage



Aim:

To describe the epidemiology of kidney failure in Aotearoa New Zealand, and assess the impact of residential location on access to kidney transplantation.

Health services research

Methods

Methods: (1) Data sources

Data linkage

ANZDATA end-stage kidney
disease incident patient cohort
(New Zealand 2006-2019)

Study cohort
(n=7,704)



ANZDATA = Australia and New Zealand
Dialysis and Transplant Registry

Data linkage

ANZDATA end-stage kidney
disease incident patient cohort
(New Zealand 2006-2019)

Study cohort
(n=7,704)

ANZDATA = Australia and New Zealand
Dialysis and Transplant Registry

ANZDATA Course of
Treatment Dataset
(2006-2019)

*Initial KRT modality, live
donor transplantation dates*

Data linkage

ANZDATA end-stage kidney
disease incident patient cohort
(New Zealand 2006-2019)

Study cohort
(n=7,704)

ANZDATA = Australia and New Zealand
Dialysis and Transplant Registry

ANZDATA Course of
Treatment Dataset
(2006-2019)

*Initial KRT modality, live
donor transplantation dates*

National Minimum
Dataset (admitted
patient records,
2001-2019)

*Domicile, coded hospital
ICD-10-AM diagnoses*

*Calculation of Charlson
Comorbidity Index &
M3 Multimorbidity Index*

Data linkage

ANZDATA end-stage kidney
disease incident patient cohort
(New Zealand 2006-2019)

Study cohort
(n=7,704)

ANZDATA = Australia and New Zealand
Dialysis and Transplant Registry

ANZDATA Course of
Treatment Dataset
(2006-2019)

*Initial KRT modality, live
donor transplantation dates*

National Minimum
Dataset (admitted
patient records,
2001-2019)

*Domicile, coded hospital
ICD-10-AM diagnoses*

*Calculation of Charlson
Comorbidity Index &
M3 Multimorbidity Index*

New Zealand Blood
Service waitlisting data
(2006-2019)

*Date of deceased donor
waitlisting*

Data linkage

ANZDATA end-stage kidney
disease incident patient cohort
(New Zealand 2006-2019)

Study cohort
(n=7,704)

ANZDATA = Australia and New Zealand
Dialysis and Transplant Registry

ANZDATA Course of
Treatment Dataset
(2006-2019)

*Initial KRT modality, live
donor transplantation dates*

National Minimum
Dataset (admitted
patient records,
2001-2019)

*Domicile, coded hospital
ICD-10-AM diagnoses*

*Calculation of Charlson
Comorbidity Index &
M3 Multimorbidity Index*

New Zealand Blood
Service waitlisting data
(2006-2019)

*Date of deceased donor
waitlisting*

Domicile mapping files

*1. District Health Board
(DHB) jurisdictions*

*2. New Zealand Index of
Deprivation*

*3. Rural-urban
Geographic
Classification for Health
(GCH)*

Methods: (2) Descriptive epidemiology

Incidence calculations

- Direct age-standardised incidence
- Population data from Stats NZ⁴
- Case numbers and population data were categorised by:
 - Calendar year
 - 5-year age bands
 - Sex
 - DHB
- World Health Organization Standard Population Distribution.⁵

Methods: (3) Multiple logistic regression

Key outcomes of interest:

- 1) Deceased donor waitlisting,
- 2) Live donor transplantation, or
- 3) Either of 1) or 2)



within 6 months after starting KRT (at age 2-64 years).

Results

Cohort characteristics

Total number of people starting KRT in NZ, 2006-2019	7,704
Age at KRT start, median (IQR)	58 years (48-68)
Sex	
Male	4,633 (60%)
Female	3,071 (40%)
Ethnicity	
European	2,975 (39%)
Māori	2,380 (31%)
Pacific	1,605 (21%)
Asian	640 (8%)
Other ethnicity	74 (1%)
Rurality (GCH code)	
Urban (U1, U2)	6,271 (81%)
Rural (R1, R2, R3)	1,402 (18%)


Trends in incidence of KRT in New Zealand, 2006-2019




Key findings:

1. The epidemiology of kidney failure and multimorbidity burden is highly variable across Aotearoa New Zealand


Age-standardised
incidence of KRT,
2006-2019



Age-standardised
incidence of KRT,
2006-2019



Rurality of
patients
starting KRT




% of patients with
a rural address*:


≤9%
10-19%
20-39%
40-59%
≥60%

*Geographic Classification for Health
R1-R3 area, based on domicile


Age-standardised
incidence of KRT,
2006-2019




Rurality of
patients
starting KRT




Socio-economic
index of patients
starting KRT




*NZDep index of 9-10




Age-standardised
incidence of KRT,
2006-2019





Socio-economic
index of patients
starting KRT



Rurality of
patients
starting KRT




Multimorbidity upon
starting KRT




*Estimated 10-year survival $\leq 53\%$


Age-standardised
incidence of KRT,
2006-2019




Rurality of
patients
starting KRT




Socio-economic
index of patients
starting KRT




Multimorbidity upon
starting KRT




?



Proportion of people starting KRT with Charlson Comorbidity Index $\geq 2^*$: trend over study period (2006-2019)



Multimorbidity upon starting KRT







*Estimated 10-year survival of $\leq 53\%$

Key findings:


2. Living in a non-transplanting region is independently associated with disadvantage in accessing kidney transplantation

Region categories


-  *'Transplanting regions'* = District Health Boards (DHBs) containing a transplant unit, or adjacent to and staffed by a transplanting DHB throughout the study period.
-  *'Intermediate regions'* = DHBs with on-site nephrologists that refer patients directly to a transplant unit or received visiting transplant unit staff.
-  *'Remote regions'* = DHBs in which patients require referral to another DHB for nephrology review, followed by a second referral to a transplant unit.



Time between starting KRT and deceased-donor transplant waitlisting (years),
by region category in NZ, 2016-2019




Multiple logistic regression analysis: waitlisting or live donor transplantation by **6 months** after starting KRT






Note: ethnicity was also included in this model

With interaction term (change over time)

With interaction term (between region category and year category):



Trend in proportion of patients waitlisted or transplanted within 6 months of starting KRT, New Zealand, 2006-19



KRT = kidney replacement therapy; KPI = key performance indicator.
Note: includes patients aged 2-64 years.

Key findings:

3. People of Māori or Pacific ethnicity were also independently disadvantaged in waitlisting and live donor transplantation

Multiple logistic regression analysis: ethnicity comparison

Outcomes:

Waitlisting / live donor transplantation
by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral


Multiple logistic regression analysis: ethnicity comparison

Outcomes:


Waitlisting / live donor transplantation by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



* = reference category;
 OR = odds ratio




Multiple logistic regression analysis: ethnicity comparison

Outcomes:


Waitlisting / live donor transplantation by **6 months** after starting KRT

Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



* = reference category;
 OR = odds ratio




Multiple logistic regression analysis: ethnicity comparison

Outcomes:

Waitlisting / live donor transplantation by **6 months** after starting KRT


Adjusted for:

- Region category (transplanting / intermediate / remote)
- Age
- Sex
- Socioeconomic quintile
- Body mass index
- M3 Multimorbidity Score
- Late referral



With interaction term (change over time)





With interaction term (between ethnicity and year category):



* = reference category

p value for interaction term (ethnicity) x (year category) = **0.046**



Trend in proportion of patients waitlisted or transplanted within 6 months of starting KRT, New Zealand 2006-19 – by ethnicity group (unadjusted)




KRT = kidney replacement therapy; KPI = key performance indicator.
Note: includes patients aged 2-64 years.

Geo-spatial mapping

Incidence of KRT, by
Territorial Authority,
2006-2019 (per 100,000
population)



Count of patients starting
KRT, by District Health Board,
2006-2019




Auckland

Waikato 2006-2019


Zoom to


Count of patients starting kidney replacement therapy (KRT)
in Waikato, 2006-2019



Note: Number in column indicates total count (dialysis and pre-emptive transplantation)

Dunedin





Summary

Our methods

Variation in KRT rates

Dialysis heatmap

Rurality

Socioeconomic index

Multimorbidity

Late referral

Key performance indicator: →

Late referral

ANZDATA captures whether patients were referred to a nephrology service at a late stage (**within 3 months of starting KRT**).


Rates of late referral are shown in this interactive map, ranging from 10% (in

⊕ Auckland DHB) to 24% (in

⊕ Whanganui DHB).

Late referral

Proportion of patients referred late (within 3 months of starting KRT), 2006-2019




Late referral


ANZDATA captures whether patients were referred to a nephrology service at a late stage (**within 3 months of starting KRT**).

Rates of late referral are shown in this interactive map, ranging from 10% (in [Auckland DHB](#)) to 24% (in [Whanganui DHB](#)).

Late referral



Proportion of patients referred late (within 3 months of starting KRT), 2006-2019





Waitlisting or transplantation within 6 months of starting KRT

Proportion of patients (aged 2-64 years) waitlisted or transplanted within 6 months of starting KRT




This map (1/3) shows the proportion of patients in each DHB that were **waitlisted or transplanted within 6 months of starting KRT**.

Darker blue indicates a higher rate.

To show the **trend over time**, click on a region and scroll down in the pop-up box.

The icon at the bottom-left of the map displays the **legend**.




This map (1/3) shows the proportion of patients in each DHB that were **waitlisted or transplanted within 6 months of starting KRT**.

Darker blue indicates a higher rate.

To show the **trend over time**, click on a region and scroll down in the pop-up box.

The icon at the bottom-left of the map displays the **legend**.




Auckland

Waikato (aged 2-64 years)

🔍 Zoom to

Trend in proportion of patients starting dialysis with planned access - Waikato, 2006-2019



Map 3/3 shows the proportion of dialysis patients that **started dialysis with planned access** (arteriovenous fistula/graft or peritoneal dialysis).

Darker green indicates a higher rate of planned access.

To show the **trend over time**, click on a region and scroll down in the pop-up box.

Dunedin

Key findings:

1. The epidemiology of kidney failure and multimorbidity burden is highly variable across Aotearoa New Zealand
2. Living in a non-transplanting region was independently associated with disadvantage in accessing kidney transplantation
3. People of Māori or Pacific ethnicity were also independently disadvantaged in waitlisting and live donor transplantation.

References:

1. Wong G, Howard K, Chapman JR, Chadban S, Cross N, Tong A, et al. Comparative survival and economic benefits of deceased donor kidney transplantation and dialysis in people with varying ages and co-morbidities. *PLoS One*. 2012; 7(1):e29591.
2. Tonelli M, Wiebe N, Knoll G, Bello A, Browne S, Jadhav D, et al. Systematic Review: Kidney Transplantation Compared With Dialysis in Clinically Relevant Outcomes. *American Journal of Transplantation*. 2011; 11(10):2093–109.
3. ANZSN Key Performance Indicator (KPI) Working Group. A Nephrology KPI Program for Australia and Aotearoa New Zealand - Report of the Key Performance Indicator Working Group. Nov 2020.
4. Stats NZ. Subnational population estimates (DHB, DHB constituency), by age and sex, at 30 June 1996-2022 (2015 boundaries), 2023.
5. Ahmad OB, Boschi-Pinto C., Lopez AD, Murray CJL, Lozano R, Inoue M. Age standardization of rates: a new WHO standard, in *GPE Discussion Paper Series: No.31*. 2001, EIP/GPE/EBD. World Health Organization.

Acknowledgements:



- **Research supervisors:** Dr Nicole De La Mata, Prof Angela Webster, Dr Nick Cross
- **ASSET Team:** Dr Ben Beaglehole, Dr Ian Dittmer, Dr John Irvine, Mr John Kearns, Dr Curtis Walker, Dr Heather Dunckley, Ms Merryn Jones, A/Prof Patrick Kelly, Prof Kate Wyburn, Ms Rachel Cutting, Dr Melanie Wyld
- **The Ross Bailey Nephrology Trust**
- Human Research Council Activation Grant 2 HRC 20/1225 (ASSET Project)
- Prof Tim Driscoll, University of Sydney School of Public Health (Public Health Training Supervisor)
- A/Prof James Stanley, Prof Diana Sarfati, A/Prof Jason Gurney - Multimorbidity project, University of Otago - Wellington (M3 Multimorbidity Index R code)
- Mr James Hedley, University of Sydney (adapted Charlson Comorbidity Index R Code)
- Mr Ray Wibrow, Digital Enablement / Pūnaha Tōrire, Te Matau a Māui Hawke's Bay
- University of Otago – Rural-urban classification for NZ health research and policy